Brief: Minerva Neurosciences Announces Update On New Drug Application (NDA) For Roluperidone
10/05/2023 13:53
May 10 (Reuters) - Minerva Neurosciences Inc NERV.O :
* MINERVA NEUROSCIENCES ANNOUNCES UPDATE ON ITS NEW DRUG
APPLICATION (NDA) FOR ROLUPERIDONE FOR THE TREATMENT OF NEGATIVE
SYMPTOMS IN SCHIZOPHRENIA
* MINERVA NEUROSCIENCES INC - FDA CONFIRMS ACCEPTANCE OF
FILING OF
NDA FOR ROLUPERIDONE
* MINERVA NEUROSCIENCES INC - FDA HAS ASSIGNED A
PRESCRIPTION DRUG
USER FEE ACT (PDUFA) GOAL DATE OF FEBRUARY 26, 2024
* MINERVA NEUROSCIENCES INC - FDA HAS ASSIGNED A
PRESCRIPTION DRUG
USER FEE ACT (PDUFA) GOAL DATE OF FEBRUARY 26, 2024
Source text for Eikon: ID:nGNX7ZS5Y5
Further company coverage: NERV.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Minerva Neurosciences
See all newsU.S. RESEARCH ROUNDUP-Cisco, Fox Corp, Target
Brief: Minerva Neurosciences Provides Second Quarter 2026 Financial Results And Business Updates
Brief: Minerva Neurosciences - To Offer And Sell Up To $75 Million In Common Stock Through Leerink Partners
Brief: Minerva Announces Leadership Transition
Minerva Neurosciences Q4 net loss widens on non-cash financing charges